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Abstract (150-250 words, 250 words) 
Introduction It was postulated that antibiotics including macrolides could be used for secondary 
prevention of coronary heart disease but recent studies showed that macrolides increase the 
cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with 
macrolides regarding duration of effect and risk factors; and explore the potential effect of statins 
for the prevention of cardiovascular events due to macrolide use.   
Methods Several electronic databases(PubMed, EMBASE, Cochrane library) were searched to 
identify eligible studies. Observational studies and randomized controlled trials(RCTs) that 
investigated the association between macrolides and cardiovascular events in adults aged≥18 years 
were included. Meta-analysis was conducted to investigate the short and long-term risks of 
cardiovascular mortality, myocardial infarction, arrhythmia and stroke. Methodological quality 
was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration’s tool. The body of 
evidence was evaluated by the Grading of Recommendations Assessment, Development, and 
Evaluation guidelines.  
Results Observational studies were found to have short-term risk of cardiovascular outcomes 
including cardiovascular mortality, myocardial infarction and arrhythmia associated with 
macrolides but no risk was found in RCTs. However no association for long-term risk (>3 years) 
was observed in observational studies or RCTs. 
Limitations The included studies reported different units of denominators for absolute risk and 
used different outcome definitions, which might increase the heterogeneity. 
Conclusions More studies are required to investigate the short-term cardiovascular outcomes 
associated with different types of macrolides. Future studies are warranted to evaluate the effect 
of statins for preventing excess acute cardiovascular events associated with clarithromycin or other 
macrolides. 
Keypoints 
 The short-term risk of cardiovascular outcomes associated with macrolides was found in 
observational studies but not in randomised controlled trials. 
 No long-term cardiovascular risk (>3 years) associated with macrolides was observed. 
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 There was limited evidence for the use of statins to prevent excess acute cardiovascular 
events associated with clarithromycin or other macrolides. 
1 Introduction 
In the past decades, it was postulated that antibiotics could be used for the treatment of Chlamydia 
pneumoniae in order to prevent further cardiovascular events, primarily because C. pneumoniae 
was found to be associated with atherosclerosis and coronary heart disease [1, 2]. Several clinical 
trials were conducted to investigate this association using the macrolide antibiotics as exposure 
but most of them used a small sample size [3-9]. Conflicting results were found and there was only 
limited evidence for a beneficial effect. A meta-analysis including randomized controlled trials 
(RCTs) found no evidence for antibiotics use to prevent further myocardial infarction [10]. 
Surprisingly, one of the macrolides, clarithromycin, was shown to have a higher risk of 
cardiovascular events versus placebo in a RCT (Effect of Clarithromycin on Mortality and 
Morbidity in Patients with Ischemic Heart Disease trial [CLARICOR trial]) [11]. Recent 
observational studies also found an elevated risk of cardiovascular events associated with 
macrolides [12-15] particularly clarithromycin, but the duration of the effects remained unclear 
[12, 15]. It was proposed that short-term exposure to clarithromycin could activate inflammatory 
macrophages, which could lead to an accumulation of lipids and vulnerable plaques in long-term, 
leading to an increased long-term risk of cardiovascular mortality [16, 17]. In addition, the clinical 
implications of the risk factors for cardiovascular events associated with macrolides have not yet 
been reported. Current literature suggests that statins may have a potentially protective effect on 
cardiovascular mortality associated with clarithromycin use [17, 18]. The postulated protective 
effect of statins was its inhibition of HMG-CoA reductase for reducing cholesterol, which results 
in reducing plague formation and lowering the risk of plaque rupture [18]. Due to the anti-
inflammatory effects of statins, it was also suggested the reduction of C-reactive protein may lower 
the cardiovascular risk [18] but one study showed no statistically significant cardiovascular risk 
among clarithromycin users receiving statins [18]. However, the evidence has not yet been 
systematically evaluated. 
This review aims to evaluate the evidence available from those studies that investigated the 
cardiovascular effects amongst those patients receiving macrolides in terms of duration effect 
and study designs. We have also summarized the current evidence of risk factors for 
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cardiovascular risk associated with the macrolide antibiotics and the suggested protective effect 
of statins in the prevention of cardiovascular events associated with clarithromycin use in the 
narrative review.2 Methods 
2.1 Search Strategy and Data Sources 
This systematic review was performed in accordance with Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Statement [19]. The protocol of this 
systematic review is available online from the website of the Centre for Safe Medication Practice 
and Research (http://www.pharma.hku.hk/sweb/CSMPR/). We searched electronic databases as 
the main information source on 6 May 2016 and updated the search on 3 February 2017. PubMed, 
EMBASE Classic + EMBASE 1980- via Ovid and the Cochrane library were searched using 
keywords and/or medical subject headings including ‘sudden death’, ‘cardiovascular diseases’, 
‘cardiac death’, ‘cardiac mortality’, ‘heart diseases’, ‘heart infarct’, ‘myocardial infarct’, ‘coronary 
disease’, ‘coronary artery disease’,  ‘heart attack’, ‘out-of-hospital cardiac arrest’, ‘myocardial 
ischemia’, ‘angina’, ‘angina pectoris’, ‘arrhythmia’, ‘ventricular fibrillation’, ‘brain ischemia’, 
‘stroke’, ‘clarithromycin’, ‘azithromycin’,  ‘erythromycin’, ‘roxithromycin’. There is no specific 
publication time limit for the search in PubMed and Cochrane Library. For the EMBASE 1980 –
via Ovid, the time period of the database for the search was from 1980 to 1 February 2017 in the 
updated search. Supplementary material 1 (Online Resource 1) shows the search strategy. Potential 
studies were retrieved after the screening of title and abstract (AYW). A reference list of the 
retrieved studies was also reviewed for further identification of potential eligible studies (AYW).  
2.2 Study Selection 
We included published RCTs and observational studies (including cohort, nested case-control, 
case-control, self-controlled case series, case-crossover or case-time-control studies) that 
investigated the association between macrolides and cardiovascular events in adults aged ≥18 
years old. Studies that did not report any cardiovascular events as an outcome or specify the types 
of cardiovascular events were excluded. Studies examining drugs other than macrolides or those 
using other macrolides as comparator only were also excluded. We also excluded conference 
abstracts, pharmacovigilance signal detection studies, animal studies or studies in languages other 
than English or Chinese. Two authors determined the eligibility and inclusion of studies in 
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systematic review and meta-analysis independently (AYW, SA) and the discrepancies were 
resolved by consensus through discussions. 
2.3 Data Collection Process and Quality Assessment 
After searching the electronic databases, Endnote X7 was used to store all the citations of identified 
articles. Data for outcomes were extracted independently by two authors (AYW, SA) and the 
discrepancies were resolved by consensus through discussions. Data extraction form was compiled 
to record items in PICO approach such as data source, study period, region, study design, inclusion 
criteria, exclusion criteria, exposure of interest, follow-up period, outcomes of interest and risk 
factors for cardiovascular risk associated with macrolides. There were multiple studies using the 
data from the same source. As they reported results in different follow-up periods in different 
reports [11, 20, 21], the reported measures of effect were extracted and pooled according to 
different follow-up periods. For one report of multiple studies which reported estimates from 
different cohorts of patients, we extracted the data from different cohorts [12, 15, 22, 23]. Each 
cohort could contribute a proportion of weights in the meta-analysis. 
For clinical relevance, the risk of mortality outcomes or composite cardiovascular outcomes was 
selected as primary outcome. The primary outcome was defined as either cardiac mortality, 
cardiovascular mortality, sudden death, cardiac arrest, all-cause mortality or composite outcomes 
including death and/or other cardiovascular events or procedures. We performed sensitivity 
analysis to exclude studies which merely reported the risk of all-cause mortality or composite 
outcomes.  
Other cardiovascular outcomes such as myocardial infarction, arrhythmia and stroke were selected 
as secondary outcomes. As the risk of cardiovascular outcomes varied depending on the follow-
up period, we separated the analyses into short-term cardiovascular risk (≤30 days) and long-term 
cardiovascular risk (>30 days). Sensitivity analyses were also conducted to pool the estimate of 
the studies with same follow-up periods. We also performed stratified analyses in the meta-
analysis to examine the risk of cardiovascular outcomes for each type of macrolides if there were 
at least two studies available for analysis. As some cohort studies defined the comparison group 
as non-macrolide exposed group, this group of patients could be either those without using any 
antibiotics or those used antibiotics other than macrolides. We performed additional analysis to 
remove these studies to test the robustness of the primary result. Factors associated with 
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cardiovascular risk and the risk of cardiovascular mortality among patients with concomitant use 
of statins and macrolides were described as the tertiary outcome and were illustrated in the 
narrative review.  
The quality assessment was performed independently (AYW, SA) for each included study. The 
observational studies were assessed for methodological quality using the Newcastle-Ottawa scale. 
The risk of bias of the RCTs was assessed using the Cochrane Collaboration’s tool. We also 
assessed the body of evidence according to Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) guidelines [24]. 
2.4 Meta-analysis  
Measures of effect including relative risk (RR), hazard ratio (HR), odds ratio (OR) and 95% 
confidence interval were retrieved and pooled using the generic inverse variance method for 
observational studies. When the measure of effect was missing, the number of events and total 
number of subjects for each exposure group were used to estimate the measure of effect. For the 
RCTs, it was calculated by inputting data into a 2x2 contingency table. When the number of events 
for each intervention group was not available in the included RCTs, the measure of effect and the 
total number of patients for each intervention group were identified. They were entered in Review 
Manager 5.3 to obtain the standard errors for the pooled analysis [25]. The measures of effects 
were pooled according to different study designs. All summary estimates were calculated using 
random-effect model in Review Manager 5.3. We assessed the heterogeneity using the I2 statistic. 
3 Results 
3.1 Search results and study selection 
After the electronic search of three databases, we identified 5905 records of publications. There 
were 5371 articles for screening after removing the duplicates. We excluded 5075 records as they 
were animal studies, did not investigate the risk of cardiovascular outcomes associated with 
macrolides, or conference abstracts. We further screened and evaluated 296 records and 
subsequently excluded 246 records as they were not observational studies, RCTs,  or using other 
macrolides as comparators. One study was excluded as it was a pharmacovigilance signal 
generation study without any hypothesis driven process [26]. Another study which was written in 
languages other than English or Chinese was also excluded [27]. Three additional studies were 
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identified manually by reviewing the bibliography of the retrieved articles. As a result, we included 
41 studies for 49 publications in this systematic review (Fig.1). Among them, thirteen studies 
investigated the association between the cardiovascular outcomes with at least one macrolide. 
Eleven studies specifically reported cardiovascular outcomes for azithromycin, Ten studies for 
clarithromycin, five studies for roxithromycin and two studies for erythromycin. A summary table 
of the included studies and additional information for the studies included in the meta-analysis are 
presented in Supplementary material 2 and 3 (Online Resource 2 and 3). 
3.2 Methodological quality 
For observational cohort studies or self-controlled case series, the exposed and non-exposed 
cohorts were representative and could demonstrate the risk of incident outcomes in most of the 
studies. The majority of the studies used rigorous methodologies to adjust confounding. However, 
many studies did not report the follow-up rate or achieve complete follow-up. In addition, several 
cohort studies were designed to investigate short-term cardiovascular outcomes, so the follow-up 
periods were inadequate (Supplementary material 4, Online Resource 4). 
For case-control, case-crossover or case-time-control studies, the majority of the studies recruited 
representative cases and controls. All studies used age and other cardiovascular factors for 
covariate adjustment in their analyses and properly ascertained the exposure status. However, 
some studies did not clearly define the controls that they had no history of the outcomes of interest 
(Supplementary material 5, Online Resource 5). 
For RCTs, all studies used randomization method to assign exposure status with blinding of 
participants and personnel, as well as the outcome assessment in design. However, some studies 
did not clearly describe the procedures of sequence generation and allocation concealment. In view 
of these outcome measures, two trials were rated as high risk of incomplete outcome data while 
another two trials were rated as high risk of selective outcome reporting (Supplementary material 
6, Online Resource 6). Supplementary material 7 and 8 (Online Resource 7 and 8) show the 
GRADE evidence profile and summary of findings respectively. 
3.3 Primary outcome 
Fig.2 shows the forest plots for short-term primary outcome in different study designs. A higher 
odds of macrolide exposure was found among cases who had cardiac mortality than that for 
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controls (OR 1.72; 95% CI 1.09-2.73) during the current use in five case-control or case-time-
control studies [23, 28-31]. The current use of macrolides ranged from 7 to 30 days. Only one 
study reported the risk of outcome in 30 days for clarithromycin [23]. After removing the result 
for clarithromycin in this study, the risk of cardiac mortality was similarly observed (OR 1.81, 
95% CI 1.12-2.93). There were ten cohort studies or self-controlled case series analysis examining 
the risk of primary outcome associated with macrolides [12-14, 22, 32-37]. Similar to case-control 
studies, an increased risk was found (RR 1.24; 95% CI 1.04-1.49) with heterogeneity of 90% 
during the current use (5-14 days). When we excluded those studies that reported all-cause 
mortality or composite outcomes, the risk found was similar [RR 1.61; 95% CI 1.18-2.20] with a 
decreased heterogeneity of 73%. For additional analyses, studies defining the comparison group 
as non-macrolide exposed group only reported the risk of short-term primary outcome. Similar to 
the primary analysis, an increased risk was still found [RR 1.29; 95% CI 1.07-1.57)]. For RCTs 
[20, 38-41], all studies reported an all-cause mortality or composite outcomes such as severe 
recurrent angina, acute myocardial infarction, or cardiac procedures for approximately 30 days 
follow-up period. The random-effects summary estimate was 0.99 (95% CI 0.74-1.34). We 
estimated the risk differences ranged from 30.9 to 92.7 per 1 million patients for observational 
studies using GRADE guideline. The quality of evidence was low and very low for case-control 
studies and cohort studies respectively. However, the quality of evidence was moderate in RCTs 
which found no increased risk of short-term primary outcome. 
No case-control studies reported the long-term primary outcome but eight cohort studies or self-
controlled case series analysis were identified (Fig 3) [15, 22, 33, 37, 42-45]. We could not observe 
any increased risk of primary outcome associated with macrolides (RR 1.05; 95% CI 0.91-1.22) 
with heterogeneity of 54%. The follow-up period ranged from 31 days to 5 years. We conducted 
sensitivity analyses for at least two studies reporting the effect estimates in the same follow-up 
period (90 days, 1 year, 1-2 year, and 2-3 years). In one year follow-up, two observational studies 
with three cohorts showed an overall increased risk of 1.41 (95% CI 1.23-1.62) [15, 42]. All other 
sensitivity analyses showed no increased long-term risk (data not shown). Apart from 
observational studies, we included 14 RCTs in another analysis [3-9, 21, 40, 46-50] with a RR of 
1.03 (95% CI 0.96-1.10). Similarly, we conducted sensitivity analyses for studies which had same 
follow-up periods (90 days, 180 days, 1 year, 2 years, and ≥3 years). We also excluded studies for 
reporting all-cause mortality or composite cardiovascular outcomes. All sensitivity analyses 
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showed no increased risk of long-term primary outcome (data not shown). The quality of evidence 
was low for cohort studies due to relatively high heterogeneity across studies in the primary 
analysis but that of RCTs was moderate. 
3.4 Myocardial infarction 
Fig.4 shows the forest plots for short-term myocardial infarction in different study designs. One 
case-control study in two publications reported the short-term myocardial infarction and showed 
no increased risk for exposure to erythromycin 14 days prior to the index date [51, 52]. After 
pooling the result with a case-crossover analysis which investigated clarithromycin [37], the risk 
was not significant (OR 1.35; 95% CI 0.57-3.19). Two studies reported the risk of acute myocardial 
infarction with clarithromycin using both cohort and self-controlled case series study designs [37, 
44]. Using results from self-controlled case-series analyses which could eliminate time-invariant 
confounding, we observed an increased pooled RR of 3.53 (95% CI 2.25-5.54). Although two 
studies used different follow-up periods (14 days and 30 days), both studies individually showed 
increased short-term risk of myocardial infarction. In contrast, no increased risk of myocardial 
infarction, unstable angina or severe recurrent ischemia for clarithromycin and roxithromycin 
versus placebo could be found for 30 days follow-up periods in three RCTs [3, 20, 38] (RR 0.65; 
95% CI 0.24-1.75). Both cohort studies and RCTs had moderate quality of evidence for short-term 
myocardial infarction and we estimated risk difference of 1787.0 per 1 million patients for cohort 
studies. 
For long-term myocardial infarction (Fig.5), two case-control studies [53, 54] and one case-time-
control study [44] did not show an increased long-term risk (OR 0.98; 95% CI 0.89-1.08). A 
marginal increased risk of myocardial infarction could be observed in cohort studies or self-
controlled case series analyses (RR 1.10; 95% CI 1.04-1.17) but the follow-up periods varied 
considerably from 31 days to 3 years [15, 33, 37, 43, 44, 55]. However, when studies with the 
same follow-up periods were combined, no increased risk could be observed for most of the 
follow-up periods (90 days, days 31-90 since prescription start date, days 91-365, 1-2 year, and 2-
3 year) (data not shown). Notably, an increased RR of 1.11 (95% CI 1.03-1.19) was observed only 
for 90 days follow-up due to the relatively high weight (99.0%) of a study which included patients 
with pneumonia and aged≥65 [33]. A total of 13 RCTs were identified and no increased risk of 
long-term myocardial infarction and/or unstable angina for macrolides could be observed (RR 0.95; 
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95% CI 0.87-1.04) versus placebo [3-9, 21, 40, 46, 47, 49, 50]. As the follow-up period varied 
between RCTs, we separated the analyses for follow-up periods of 90 days, 180 days, 1 year, 2 
years and ≥3 years respectively. All analyses showed no significant difference of risk for long-
term myocardial infarction versus placebo (data not shown). With the use of GRADE guideline, 
all study designs showed low quality of evidence that there was no increased or marginal 
significant long-term risk of myocardial infarction in the primary analysis. 
3.5 Arrhythmia 
A case-crossover study showed an increased risk of arrhythmia associated with H. pylori therapy 
containing clarithromycin [37]. There were six cohort studies reporting a short-term risk of 
arrhythmia associated with macrolides [22, 32, 34, 36, 37, 44] and no increased risk was observed 
(RR 1.36, 95% CI 0.97-1.92) (Fig.6). No RCT was identified in reporting the short-term risk of 
arrhythmia associated with macrolides. In GRADE, there was only very low quality of evidence 
for an increased short-term risk of arrhythmia due to serious risk of bias and high heterogeneity in 
the primary analysis. We estimated the risk difference of 171.7 per 1 million patients for case-
crossover study. 
One case-control study [56] which separately reported the OR for each type of macrolides and one 
case-time-control study [44] were identified to report the long-term risk of arrhythmia (Fig.6). 
Only clarithromycin and erythromycin were shown to have a higher risk of long-term arrhythmia 
but not with other macrolides in the case-control study [56]. The pooled estimate did not give an 
increased risk (OR 1.18; 95% CI 0.96-1.44). Six cohort studies or self-controlled case series 
analysis [15, 22, 33, 37, 44, 56] reported that the pooled estimate for long-term arrhythmia was 
1.10 (95% CI 0.99-1.21) with heterogeneity of 69%. However, when results from at least two 
studies with the same follow-up periods were combined, no increased risk could be found (data 
not shown). No RCT was identified to report the long-term risk of arrhythmia associated with 
macrolides. Similarly with short-term arrhythmia, we could only obtain very low quality evidence 
for no increased long-term risk of arrhythmia in observational studies using GRADE. 
3.6 Stroke 
For short-term stroke (Fig.7), the overall RR was 1.45 (95% CI 0.92-2.29) in two self-controlled 
case series analyses [37, 44]. Despite different follow-up periods (14 and 30 days), both studies 
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showed no significant difference of risk of stroke during risk period versus baseline [37, 44]. 
Similar result was obtained for two RCTs with follow-up periods of 4 days [38] and 30 days [20] 
respectively (RR 1.06; 95% CI 0.22-5.02). We found a moderate quality of evidence for two cohort 
studies and two RCTs and low quality of evidence for one case-crossover study using GRADE. 
No increased long-term risk of stroke could be observed in three observational studies [37, 43, 44] 
(RR 1.07; 95% CI 0.80-1.42) and eight RCTs [4, 6, 9, 11, 46, 48-50] (RR 1.13; 95% CI 0.91-1.41) 
(Fig.7). All sensitivity analyses that combined the same follow-up periods for cohort studies (90 
days, days 31-90 since prescription start date, days 91-365, 1-2 year and 2-3 year) and for RCTs 
(2 and ≥3 years) showed no long-term risk of stroke associated with macrolides versus placebo 
(data not shown). We found moderate and low quality of evidence for observational studies and 
RCTs respectively using GRADE. 
3.7 Stratified analyses for each type of macrolides 
Due to the limited number of available studies for erythromycin, we did not have sufficient number 
of studies to perform meta-analyses for all outcomes. We could only observe an increased long-
term risk of arrhythmia reported in a study using new antiarrhythmic prescriptions as a proxy of 
incident arrhythmia [56]. A case-control study showed an increased risk for exposure to macrolides 
7 days prior to the date of sudden death [23]. Another cohort study also demonstrated an increased 
short-term risk of cardiac death associated with erythromycin and the effect was pronounced 
among patients who concurrently used cytochrome P-450 3A (CYP3A) inhibitors [14] 
(Supplementary material 9, Online Resource 9). 
With clarithromycin, no increased risk of short or long-term primary outcome was observed across 
study designs. However, the heterogeneity of the pooled estimate was very high among cohort 
studies (83%). After excluding the study of Chou et al. [32] in the analysis, the risk of short-term 
primary outcome significantly increased (RR 1.40; 95% CI 1.12-1.76) with heterogeneity of 37%. 
An increased short-term risk of myocardial infarction was observed in observational studies but 
not in RCTs. No increased long-term risk of myocardial infarction associated with clarithromycin 
was shown across study designs. We could observe a short-term increased risk of arrhythmia in a 
case-crossover study (RR 2.49; 95% CI 1.09-5.69) [37] and no increased risk in four cohort studies 
[22, 32, 37, 44]. For long-term arrhythmia, we observed a marginal increased risk in two case-
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control studies (OR 1.19; 95% CI 1.05-1.35) [44, 56]. For stroke, no increased risk in all follow-
up periods could be found across study designs. (Supplementary material 10, Online Resource 10) 
With azithromycin, we could not observe any significant increased short-term or long-term risk of 
primary outcome in cohort studies or RCTs. Although the risk did not reach statistical significance, 
the risk of short-term primary outcome was shown to be doubled in cohort studies and RCTs. No 
study investigated the short-term risk of myocardial infarction. A cohort study which conducted 
among patients with high baseline cardiovascular risk showed an increased long-term risk of 
myocardial infarction in 90 days [33] but five RCTs did not show an overall higher risk ratio of 
0.92 (95% 0.79-1.08) versus placebo [4, 7, 8, 46, 47]. A significantly increased short-term risk of 
arrhythmia was shown in two cohort studies (RR 3.04; 95% CI 1.52-6.07) [32, 34]. No long-term 
risk of arrhythmia was shown in observational studies. For stroke, no observational study could be 
identified but no long-term risk was found in three RCTs with an overall risk ratio of 1.07 (95% 
CI 0.75-1.52) [4, 46, 48] (Supplementary material 11, Online Resource 11). 
With roxithromycin, the number of observational studies was inadequate to obtain an overall effect 
summary for all outcomes. No study investigated the short-term risk of arrhythmia nor short-term 
risk of stroke associated with roxithromycin. In RCTs, there was no increased risk of primary 
outcome or myocardial infarction in all follow-up periods. In addition, no increased long-term risk 
of arrhythmia or stroke could be found (Supplementary material 12, Online Resource 12). 
3.8 Narrative review 
Supplementary material 2 (Online Resource 2) shows the identified studies which demonstrated 
subgroup analyses to explore the risk factors for cardiovascular outcomes associated with 
macrolides. Trac et al. performed several subgroup analyses and concluded that the history of 
chronic kidney disease, congestive heart failure, coronary artery disease or concurrent use of QT 
wave prolonging drugs did not significantly modify the association between macrolides and 
ventricular arrhythmia [36]. Regarding erythromycin, one cohort study reported that concurrent 
use of erythromycin and strong inhibitors of CYP3A such as nitroimidazole antifungal agents, 
diltiazem, verapamil and troleandomycin was a high risk factor for cardiac death [14]. For 
azithromycin, Mortensen et al. concluded that women had lower risk of 30-day mortality, 90-day 
mortality and myocardial infarction but the association was not significant due to small number of 
female patients in veterans administration patient population [33]. Other cohort studies reported 
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that those patients who received azithromycin had a higher risk of cardiovascular mortality versus 
non-users among patients who had high cardiovascular baseline risk [13, 35]. However, a cohort 
study conducted in Taiwan found significant cardiovascular risk with wide confidence intervals 
among patients without cardiovascular disease and those aged ≤65 years [32]. Two RCTs did not 
show differences across subgroups according to history of diabetes, hypertension and 
hypercholesterolemia [8, 46]. 
Similar to azithromycin, Schembri et al. [15] and Wong et al. [37] reported that caution should be 
taken when prescribing clarithromycin for those patients who had a high cardiovascular baseline 
risk such as history of cardiovascular diseases, hypertensive diseases or diabetes. Patients aged 
≥75 years also had higher risk of cardiovascular outcomes associated with clarithromycin versus 
amoxicillin [37]. In addition, Schembri et al. also showed that the longer the duration of 
clarithromycin administration (more than seven days) then the higher the risk of cardiovascular 
events [15]. In contrast, Svanstrom et al. found no differences across subgroups according to 
cardiovascular baseline risk but higher risk in women than men for cardiac mortality in current use 
of clarithromycin versus penicillin V [12]. 
Regarding the concomitant use of statins and clarithromycin, a subgroup analysis using data from 
a RCT found that statins has protective prognostic effect of clarithromycin against all-cause and 
cardiovascular mortality [17, 18]. The concomitant use of statins at entry with clarithromycin 
showed a non-significant protective effect of cardiovascular mortality (HR 0.68; 95% CI 0.38-
1.22) while the risk of cardiovascular mortality confined to those who did not use statins at entry 
(HR 1.90; 95% CI 1.34-2.67) in 3 years [18]. Similar results were obtained after further adjustment 
for sex, age, history of myocardial infarction and smoking. Comparing with patients who did not 
use statins at entry, the risk of all-cause mortality significantly reduced among patients with statins 
at entry (HR 0.31; 95% CI 0.20-0.49) [17]. In addition, Schembri et al. showed no significant 
differences of cardiovascular events among statins and clarithromycin users versus non-users in 
both cohorts of patients with community acquired pneumonia and chronic obstructive pulmonary 
disease given that increased risk could be found in the full cohort [15].  
4 Discussion 
4.1 Cardiovascular risk 
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In general, we found a short-term increased risk of cardiovascular mortality, myocardial infarction 
and arrhythmia associated with the use of macrolides. However, we did not find any long-term 
cardiovascular risk except for a weak association with myocardial infarction. No short or long-
term risk of stroke could be demonstrated in this study. Although we could not observe a short-
term cardiovascular risk in RCTs, this may be due to the small sample size of approximately 2000 
patients for each study group. For myocardial infarction, we estimated the risk difference was 1.79 
events per 1000 patients which may indicate that the included randomized controlled trials were 
underpowered to detect the short-term risk of myocardial infarction. With large population-based 
cohorts, observational studies with rigorous study designs and methodologies could detect rare 
events with robust estimates in short follow-up periods when compared with RCTs. Therefore, 
observational studies complemented the findings with RCTs for short-term cardiovascular 
outcomes, especially for short-term myocardial infarction given its moderate quality of evidence 
in GRADE. Importantly, we estimated 1.79 excess myocardial infarction events in short-term 
(95% CI 0.88-3.20) per 1000 patients. Further, there was no increased risk of stroke associated 
with macrolides as supported by the evidence of moderate quality in this study. 
In the current literature, there are very few studies for erythromycin and roxithromycin so the class 
effect of cardiovascular risk for macrolides remains uncertain. In the stratified analysis, we could 
only demonstrate that erythromycin increased the short-term risk of cardiac death, clarithromycin 
increased the short-term risk of myocardial infarction, while azithromycin increased the short-term 
risk of arrhythmia in observational studies. However, one pharmacovigilance study using 
healthcare data from three European countries found an increased risk of myocardial infarction 
associated with clarithromycin, azithromycin, roxithromycin and erythromycin individually 
during the current exposure using several observational study designs [26]. Due to the limited 
number of studies for macrolides other than clarithromycin, we could not rule out the possibility 
that macrolides have a class effect upon acute myocardial infarction.  
In addition, there were few studies reporting the risk factors for cardiovascular risk associated with 
macrolides. Most of the studies reported that patients who had high baseline cardiovascular risk 
had higher risk of cardiovascular outcomes for azithromycin and clarithromycin. Prescribers 
should be cautious when prescribing azithromycin and clarithromycin to these patients. In view of 
the cardiovascular protective effect of statins, currently there is only one RCT which was designed 
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to investigate the long-term risk of cardiovascular mortality and showed that statins can prevent 
the excess cardiovascular mortality associated with clarithromycin in long-term [18]. No RCT or 
observational study has been conducted to evaluate the protective effect in short-term. In contrast 
to the RCT that could find a long-term protective effect of statins for preventing the excess risk of 
cardiovascular mortality [18], our review could only find a short-term cardiovascular risk 
associated with clarithromycin. As we could not find a long-term increased cardiovascular risk, 
we could not evaluate the long-term protective effect of statins suggested by this RCT [18]. In 
addition, one cohort study reported that no differences of mortality or hospitalization among 
patients who had overlapping prescriptions of statins and clarithromycin, compared with those 
who had clarithromycin only after adjustment of age, treatment with other antibiotics, history of 
diabetes or cardiovascular disease (RR 1.02; 95% CI 0.85-1.22) [57]. Due to the limited evidence, 
more epidemiological studies are required to evaluate the findings and subsequently perform risk/ 
benefit assessment before recommendation as co-prescription of statins and clarithromycin could 
also lead to adverse interaction effects [58]. 
4.2 Strength and limitation of the review 
We updated the systematic review to analyze the risk of cardiovascular events associated with 
macrolides in terms of different follow-up periods and study designs, as well as summarize the 
risk factors and the potential cardiovascular protective effect due to the concomitant use of statins 
and clarithromycin. Similarly, Cheng et al. also reported an increased risk of cardiovascular 
mortality during current use but not former use (365 days) [59]. A study suggested that the risk of 
mortality could only be observed when the follow-up periods were extended to more than two 
years [16]. In our review, we demonstrated that there was no increased risk of cardiovascular 
mortality for more than three years of follow-up. In addition, we pooled data from studies 
conducted in different countries and thus increased the generalizability of our findings. Moreover, 
this is also the first systematic review to use GRADE guideline to evaluate the quality of evidence 
for each cardiovascular outcome associated with macrolides in a better system for further clinical 
implication. 
There are few potential limitations with our systematic review. Firstly, the heterogeneity of short-
term increased risk of primary outcome for observational studies is high which resulted in a very 
low quality of evidence. We attempted to reduce the heterogeneity by performing a sensitivity 
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analysis to remove studies reporting all-cause mortality only and gave similar result. While 
randomized controlled trials did not show an increased risk of primary outcome with moderate 
quality of evidence, these results should be interpreted cautiously due to the limited sample size. 
Future population-based observational studies should be well-designed to replicate previous 
studies so as to decrease the heterogeneity across studies for providing higher quality of evidence 
for the primary outcome. Secondly, several observational studies used different units of 
denominators for absolute risk (i.e. per prescriptions/ per patients/ per patient years), therefore we 
could not summarize the total number of patients in exposed and non-exposed groups. Despite the 
inconsistency of the studies, we estimated the absolute risk of cardiovascular outcomes from large 
population-based cohort studies and obtained a similar estimate of risk difference of cardiovascular 
mortality (30.9-92.7 per 1 million patients) reported by Cheng et al. (38.2 per 1 million treatment 
courses) [59]. Thirdly, different RCTs had different definitions of outcomes so it might lead to a 
certain degree of heterogeneity for our primary outcome. However, the heterogeneity was found 
to be very low and we also performed several sensitivity analyses to test the robustness of results 
which gave similar findings. Fourthly, we did not include studies which are in languages other 
than English and Chinese. However, only one study in Korean which should be eligible for 
inclusion presented the main findings in an English abstract. It resulted in the same result with our 
primary analysis (RR 1.03; 95% CI 0.96-1.10). Therefore, the exclusion of non-English/Chinese 
studies should not affect the interpretation of the results and conclusion of this study. 
5 Conclusion 
A short-term increased risk of cardiovascular outcome associated with macrolides but no long-
term cardiovascular risk could be observed for follow-up periods up to four years. Prescribers 
should be cautious when prescribing azithromycin and clarithromycin to patients who have high 
baseline cardiovascular risk such as history of cardiovascular diseases, hypertensive diseases or 
diabetes. Currently limited observational studies have been conducted to investigate the short-term 
risk of myocardial infarction associated with macrolides other than clarithromycin. Future studies 
are required to report subgroup analysis for important risk factors and investigate the potential 
protective short-term cardiovascular effect from the concomitant use of statins and macrolides. 
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